Kenneth Getz
Director of Sponsored Programs and Associate Professor, Tufts University School of Medicine; Founder and Chairman, CISCRP
Meet Kenneth Getz
“The development, continued regulatory approval and commercialization of immunotherapies will have the biggest impact on patients. The impact is expected to continue to grow exponentially as immunotherapies extend into disease conditions other than cancer.”